TICKERNERD
Menu
ELANELANHealthcare · Drug Manufacturers - Specialty & Generic

ELAN Stock Forecast: Elanco Animal Health, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$23
+1.36% on the day

The 17 Wall Street analysts covering Elanco Animal Health, Inc. hold a median 12-month price target of $32 — +36.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 12 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$11.6B
Ticker Nerd rank
98 / 100
Median analyst target
$32
Analysts covering
17
Revenue$1.4B+10.2% y/y
Operating income$118.0M
Net income$54.0M
Free cash flow$244.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.1%
1M
+1.9%
YTD
+2.4%
1Y
+23.4%
From 52W high
−13.7%
From 52W low
+25.7%
$18
$27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ELAN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Elanco Animal Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
98 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
95
Value
94
Volatility
85
Issuance
82
Quality
82
Accruals
77
Momentum
74
Growth
61
Size
14

Revisions (95): Analysts have, on balance, been raising their forecasts.

Growth (61): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (14): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ELAN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELAN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30$35Oct 25Jan 26Apr 26Jul 26ELANHigh $34Median $32Low $26

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
15 Buy2 Hold0 Sell
Low $26Median $32High $34

The green dot is the last close — the median target sits +36.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
6 Aug 2026KeybancMaintainsOverweight$29 → $30
6 Aug 2026UBSMaintainsBuy$31 → $33
22 July 2026Morgan StanleyMaintainsEqual-Weight$23 → $26
22 July 2026Morgan StanleyMaintainsEqual-Weight—
18 June 2026TD CowenMaintainsBuy—
18 June 2026TD CowenMaintainsBuy$31 → $32
7 May 2026CitigroupMaintainsBuy—
7 May 2026JP MorganMaintainsOverweight—
15 Apr 2026CitigroupInitiatesBuy—
25 Feb 2026KeybancMaintainsOverweight—
25 Feb 2026Morgan StanleyMaintainsEqual-Weight—
24 Feb 2026Leerink PartnersMaintainsOutperform—
19 Feb 2026JP MorganMaintainsOverweight—
22 Jan 2026Piper SandlerUpgradeOverweight—
18 Dec 2025Morgan StanleyMaintainsEqual-Weight—
9 Dec 2025BarclaysInitiatesOverweight—
21 Nov 2025KeybancInitiatesOverweight—
6 Nov 2025UBSMaintainsBuy—
20 Oct 2025UBSMaintainsBuy—
7 Oct 2025JP MorganUpgradeOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELAN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ELAN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Elanco Animal Health, Inc. returned +23.4% against +17.5% for the S&P 500, dividends included.

ELAN vs S&P 500, last 12 monthsTotal return, rebased to 100
100110120130140Oct 25Jan 26Apr 26Jul 26ELANS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ELAN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+7.1%
Analysts raising
13
Analysts cutting
0
Fundamentals

Elanco Animal Health, Inc. (ELAN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
377.1×

Cheaper than 2% of US stocks

Price / sales
2.3×

Cheaper than 49% of US stocks

Price / book
1.8×

Cheaper than 50% of US stocks

EV / EBITDA
15.2×

Cheaper than 22% of US stocks

Growth & margins
Revenue growth (YoY)
10.2%

Higher than 52% of US stocks

Earnings growth (YoY)
390.9%

Higher than 94% of US stocks

Gross margin
58.3%

Higher than 72% of US stocks

Operating margin
8.6%

Higher than 62% of US stocks

Net margin
−4.0%

Higher than 25% of US stocks

Returns & dividend
Return on equity
−3.0%

Higher than 41% of US stocks

Return on assets
1.6%

Higher than 55% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Elanco Animal Health, Inc. (ELAN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Elanco Animal Health, Inc. has a market value of $11.6B and an enterprise value of $15.3B.

  • Revenue in the twelve months to 30 June 2026: $5.0B. The latest quarter grew 10.2% year on year.

  • Net income over the same four quarters: −$199.0M, a −4.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.41.

  • Free cash flow in the twelve months to 30 June 2026: $379.0M.

  • Shares outstanding: 499.5M.

  • Trailing P/E: 377.1×; forward P/E: 18.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Elanco Animal Health, Inc. employs 9,400 people — $534K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

ELAN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ELANElanco Animal Health, Inc.$11.6B
98
NBIXNeurocrine Biosciences, Inc.$15.6B
89
ALKSAlkermes Plc$7.6B
62
VTRSViatris, Inc.$19.0B
100
LNTHLantheus Holdings, Inc.$6.5B
88
HIMSHims & Hers Health, Inc.$6.4B
17
UTHRUnited Therapeutics Corp.$21.1B
82

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Elanco Animal Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ELAN news & analysis

Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement

PRNewsWire · 11 Sept 2026neutral

Elanco Animal Health announced it will release its third quarter 2026 financial results on Friday, November 6, 2026, and will host a conference call to discuss the results. The announcement was made via press release from Indianapolis.

Why it matters — ELAN watchers will want to note the scheduled date and conference call for the upcoming quarterly earnings announcement.

Elanco to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

PRNewsWire · 10 Sept 2026neutral

Elanco Animal Health announced that it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, in Indianapolis. The company's attendance at the event was confirmed via a PRNewswire release.

Why it matters — This signals an opportunity for Elanco to present its business to investors and industry stakeholders at a major healthcare conference, which ELAN watchers may follow for updates on the company's positioning.

Elanco Director Purchases 40,000 Shares for $936,000

The Motley Fool · 4 Sept 2026positive

An Elanco director purchased 40,000 shares for $936,000, an investment that increased the insider's direct equity position by 27%. The transaction reflects increased insider ownership in the company.

Why it matters — A significant insider share purchase can signal confidence in the company's prospects, and it increases the director's alignment with other ELAN shareholders.

Elanco Scales Biologics Capabilities with Expansion of Kansas Manufacturing Facility

PRNewsWire · 26 Aug 2026positive

Elanco announced the on-time completion of a 25,000-square-foot manufacturing expansion at its Elwood, Kansas site, which bolsters its monoclonal antibody (mAb) production and support for its next-generation pipeline. The company is one of only two animal health firms with mAb solutions currently on the market.

Why it matters — ELAN watchers would care because the expansion strengthens Elanco's biologics manufacturing capabilities and leadership in the monoclonal antibody space, supporting delivery of its pipeline.

Elanco Animal Health: New Products To Support Growth

Seeking Alpha · 20 Aug 2026positive

Elanco Animal Health's new products Zenrelia and Credelio Quattro are gaining significant market share, supporting double-digit revenue growth and margin expansion. Befrena is an additional growth lever with early demand exceeding expectations, though its near-term contribution is limited by supply constraints.

Why it matters — ELAN watchers would care because adoption of the company's new product cycle is a key driver of revenue growth and margin expansion.

FAQ

Frequently asked questions about ELAN stock

What is the ELAN stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Elanco Animal Health, Inc. have a median 12-month price target of $32, with estimates ranging from $26 to $34. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELAN stock a buy right now?

Of the 17 analysts covering Elanco Animal Health, Inc., 15 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Elanco Animal Health, Inc. 98 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELAN?

As at 12 Sept 2026, Elanco Animal Health, Inc. ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (95 of 100).

Will ELAN stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +36.0% from the last close, and Ticker Nerd's factor model ranks Elanco Animal Health, Inc. 98 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELAN stock forecast for 2030?

No analyst covering Elanco Animal Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELAN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $34 over the next 12 months.

How has ELAN stock performed over the past year?

Elanco Animal Health, Inc. returned +23.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Elanco Animal Health, Inc. do?

Elanco Animal Health Incorporated is an animal health company focused on developing, manufacturing, and marketing products for pets and farm animals. Its portfolio includes treatments and preventive solutions for parasitic control, dermatology, pain management, vaccines, and other therapeutic areas used in companion animals and livestock.

What is the latest news on ELAN?

The most recent item we track (PRNewsWire, 11 Sept 2026): "Elanco Confirms Date and Conference Call for Third Quarter 2026 Financial Results Announcement". Elanco Animal Health announced it will release its third quarter 2026 financial results on Friday, November 6, 2026, and will host a conference call to discuss the results. The announcement was made via press release from Indianapolis.

Company

About Elanco Animal Health, Inc.

Elanco Animal Health Incorporated is an animal health company focused on developing, manufacturing, and marketing products for pets and farm animals. Its portfolio includes treatments and preventive solutions for parasitic control, dermatology, pain management, vaccines, and other therapeutic areas used in companion animals and livestock. The company serves veterinarians, pet owners, farmers, and producers across a wide range of species, including dogs, cats, cattle, poultry, swine, and sheep. Elanco Animal Health Incorporated also offers products used in food-animal health and production settings, supporting disease prevention and animal wellbeing in everyday care and commercial agriculture. Headquartered in Indianapolis, Indiana, Elanco Animal Health Incorporated operates as a diversified participant in the global animal health market, with a broad product mix spanning companion animal and farm animal care.

CEO Mr. Jeffrey N. Simmons · 9,400 employees · United States · https://www.elanco.com